Finland vs Senegal: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Finland
91.0%
in 2025
Senegal
91.0%
in 2025
Finland rank
59th
Senegal rank
59th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Finland
- Senegal
How they compare
Finland currently reports 91.0% against 91.0% in Senegal, a difference of 0.0%.
The two have swapped places 4 times across 18 shared years of data; in 2008 it was Senegal ahead.
Finland ranks 59th and Senegal ranks 59th of 192 countries.
Across the 3 decades both report, Finland averaged higher in 1 and Senegal in 1.
Head to head by decade
| Decade | Finland | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | β |
| 2010s | 90.1% | 53.8% | 36.3% | Finland |
| 2020s | 87.3% | 88.5% | 1.2% | Senegal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Finland or Senegal?
- Finland, at 91.0% against 91.0% in Senegal as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Finland and Senegal?
- 0.0%, with Finland ahead.
- How many years of comparable data are there for Finland and Senegal?
- 18 years are reported by both, from 2008 to 2025.
- How do Finland and Senegal rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Finland ranks 59th and Senegal ranks 59th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.